CMS and Tempus Push Continuous Care Into Reimbursable Evidence

Continuous monitoring is moving from device novelty to payment-backed clinical evidence, with reimbursement and validation becoming the new moat.

Updated

What is this trend?

CMS payment rules and Tempus-backed clinical validation are turning continuous monitoring and virtual care into evidence-based, reimbursable care pathways.

  • ACCESS links digital chronic care to outcome-based Medicare billing, not blanket device coverage.
  • Tempus’ ARPA-H study signals autonomous AI and continuous monitoring are moving toward clinical proof.
  • Value is shifting from sensors alone to workflow control, escalation, and billing-model fit.
  • Vendors need regulatory clearance plus evidence that continuous care reduces utilization.
  • Home, ambulatory, and virtual workflows are converging around reimbursable care platforms.

What’s the latest?

CMS’s ACCESS model and Tempus’ ARPA-H award extend the shift from sensing and command centers into payment-backed clinical accountability.

Inspectable AI becomes the enterprise standard, Oracle escalates the RCM platform war, and continuous care gains reimbursement proof

How it developed

  1. Ambient AI Goes Procurement-Grade, Home Monitoring Consolidates, and Medication Access Becomes Workflow Layer
    • Home Monitoring Consolidates Into Integrated Care Platforms

  2. AI moves from documentation to operating systems, capital scales proven platforms, and sensing gets continuous
    • Clinician Command Centers Take the Lead in Continuous Sensing

Go deeper

Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.

Stay ahead in HealthTech

Get the weekly brief in your inbox — the developments, what they mean by vantage, and what to do next.